Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Eur J Cancer. 2018 Dec 4;106:133–143. doi: 10.1016/j.ejca.2018.10.012

Fig. 3.

Fig. 3.

ccfDNA changes when treatment responses could not be expained by CTC change alone. Responders are defined as patients with partial or complete response; non-responders are patients with stable or progressive disease. ccfDNA level at follow-up visit after treatment initiation were compared with ccfDNA level before treatment initiation in (A) responders who had ≥ 5 CTCs or stable CTCs at follow-up visit after treatment initiation; (B) non-responders who had decreased CTCs or continuously < 5 CTCs at follow-up visits after treatment initiation, including (B1) CTCs that decreased but were still ≥ 5, (B2) CTCs that decreased from ≥ 5 to < 5, and (B3) CTCs that were continuously < 5.